Systemic therapies for unresectable primary hepatic tumors

Area of Science:

• Hepatobiliary cancers
• Medical oncology
• Clinical trial design

Background:

• Hepatocellular carcinoma (HCC) systemic therapy trials require consideration of prognostic factors.
• Clinical features like poor performance status, older age, and jaundice predict short survival in HCC patients.
• Elevated alpha-fetoprotein (AFP) levels are associated with poor prognosis in HCC.

Purpose of the Study:

• To review the efficacy of systemic therapies for hepatocellular carcinoma (HCC) and cholangiocarcinomas.
• To highlight the need for stratifying HCC patients by AFP levels in clinical trials.
• To advocate for the investigation of novel therapeutic approaches and phase II agents in HCC.

Main Methods:

• Review of numerous clinical trials evaluating single-agent and combination chemotherapy for HCC.
• Analysis of clinical trials for cholangiocarcinomas, noting limited patient numbers.
• Examination of prognostic factors influencing survival in HCC.

Main Results:

• Past clinical trials of single-agent chemotherapy for HCC have not yielded agents with response rates >20% or improved survival.
• Effective combination chemotherapy regimens for HCC remain unidentified.
• Systemic therapies for cholangiocarcinomas have not been effectively identified in clinical trials.

Conclusions:

• Current systemic therapies for HCC and cholangiocarcinomas have shown limited efficacy.
• Future HCC clinical trials must stratify patients based on AFP levels.
• Further research should focus on phase II agents in good-performance, untreated HCC patients and novel drug delivery methods.